{"id":264257,"date":"2026-09-23T12:47:46","date_gmt":"2026-09-23T07:17:46","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=264257"},"modified":"2026-09-23T12:47:46","modified_gmt":"2026-09-23T07:17:46","slug":"divis-laboratories-vs-laurus-labs-vs-syngene-international","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/divis-laboratories-vs-laurus-labs-vs-syngene-international\/","title":{"rendered":"Divi’s Laboratories vs Laurus Labs vs Syngene International: Which Stock Should You Track"},"content":{"rendered":"

Divi’s Laboratories PE 84.81, mkt cap Rs 2,48,054 crore. Laurus Labs PE 99.36, mkt cap Rs 1,08,338 crore. Syngene International PE 69.05, mkt cap Rs 15,247 crore.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Divi’s Laboratories vs Laurus Labs vs Syngene International is a side-by-side comparison of three companies from the Pharma CDMO and API space. On this comparison, Divi’s Laboratories carries a market capitalisation of about Rs 2,48,054 crore against Rs 1,08,338 crore for Laurus Labs and Rs 15,247 crore for Syngene International, with return on equity of 15.32%, 16.77% and 7.76% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.<\/p>\n<\/div>\n

Divi’s Laboratories vs Laurus Labs vs Syngene International starts with the core numbers most investors compare within the Pharma CDMO and API segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.<\/p>\n

All three names sit in the Pharma CDMO and API bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n